Kenichi Suda

Kenichi Suda

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 131 publications

Lack of impact of antibiotics and proton pump inhibitors on the efficacy of preoperative chemoimmunotherapy in locally advanced non-small cell lung cancer: A multicenter retrospective study.

Lack of impact of antibiotics and proton pump inhibitors on the efficacy of preoperative chemoimmunotherapy in locally advanced non-small cell lung cancer: A multicenter retrospective study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 18, 2025

Current Status and Future Challenges of Liquid Biopsy.

Current Status and Future Challenges of Liquid Biopsy.

Journal: Cells

Published: December 14, 2025

Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation.

Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation.

Journal: Clinical lung cancer

Published: December 10, 2025

Corrigendum to "The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic Oncology Vol. 20 No. 10: 1423-1440]".

Corrigendum to "The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic Oncology Vol. 20 No. 10: 1423-1440]".

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 01, 2025

Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study).

Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 14, 2025

Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.

Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.

Journal: JTO clinical and research reports

Published: September 09, 2025

Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations-An In Vitro Study.

Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations-An In Vitro Study.

Journal: Cells

Published: July 30, 2025

Utility and Future Perspectives of Circulating Tumor DNA Analysis in Non-Small Cell Lung Cancer Patients in the Era of Perioperative Chemo-Immunotherapy.

Utility and Future Perspectives of Circulating Tumor DNA Analysis in Non-Small Cell Lung Cancer Patients in the Era of Perioperative Chemo-Immunotherapy.

Journal: Cells

Published: July 27, 2025

Overexpression of PPM1G promotes cell metabolism and activates the NOTCH signaling pathway in lung adenocarcinoma.

Overexpression of PPM1G promotes cell metabolism and activates the NOTCH signaling pathway in lung adenocarcinoma.

Journal: Translational lung cancer research

Published: June 06, 2025

Similar Trend in Benefit of Adjuvant Platinum in Lung Cancer Patients Irrespective of Epidermal Growth Factor Receptor Mutation Status.

Similar Trend in Benefit of Adjuvant Platinum in Lung Cancer Patients Irrespective of Epidermal Growth Factor Receptor Mutation Status.

Journal: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

Published: April 29, 2025

Safety Profile of Neoadjuvant Chemoimmunotherapy With Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer in the Real World (CReGYT-04 Neo-Venus).

Safety Profile of Neoadjuvant Chemoimmunotherapy With Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer in the Real World (CReGYT-04 Neo-Venus).

Journal: The Annals of thoracic surgery

Published: April 18, 2025

Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance.

Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance.

Journal: Cancer research communications

Published: March 30, 2025

Showing 1-12 of 131

Last Updated: 09/26/2026